Total revenue for the year ended December 31, 2025, was $1,863,400, an increase of 17% over 2024. The Vycor Medical division (VBAS) generated revenue of $1,796,070, an 18% increase over 2024, with most growth from international markets and continued US sales. The NovaVision division, which remains in development, generated revenues of $67,330, an 8% decrease from 2024. The company reported a GAAP operating profit of $33,900 for 2025, a significant improvement from an operating loss of $(9,145) in 2024. Non-GAAP operating profit increased by $64,333 to $145,881 in 2025, compared to $81,548 in 2024. Gross profit for 2025 was $1,561,107, an 11% increase over 2024, with a gross margin of 83% (down from 89% in 2024). Seven new peer-reviewed studies on the ViewSite Brain Access System (VBAS) were published in 2025, bringing the total to 50, highlighting clinical advantages. A new clinical study validated NovaVision's NeuroEyeCoach for effective home-based use, aligning with global healthcare trends.